OK, so it might not be on track to finish the year as the best drug stock for 2007, but Forest Laboratories
The drug company checked in Tuesday morning with its fiscal Q2 earnings, which proved a mixed bag. The stock is being punished by roughly 5%, because Forest Labs posted a 5% decrease in earnings per share. A licensing charge related to one of its investigational drug candidates hurt its bottom line.
The company posted an 8.2% increase in net sales versus its year-ago quarter. This improvement fell slightly short of Wall Street's expectations, but there was a silver lining for shareholders.
The good news included a 7% increase in net sales of Forest Labs' cash crop, Lexapro, versus the year-ago Q2. Lexapro is an antidepressant that now accounts for about 61% of total revenue. Also, the company slightly increased its full-year earnings guidance, reporting that it had repurchased roughly 1.6% of its diluted shares during Q2.
In scanning some of the other candidates for the best drug stock of the year, the results have not been pretty. Genentech
While Forest Labs may not be the likely candidate to win this contest, the way that things are shaping up will make for an interesting finish.
For related Foolishness:
More from The Motley Fool
Anti-Depressants: The Secret to Preventing Alzheimer's?
Scientists are exploring the ways serotonin reuptake inhibitors might be able to slow Alzheimer's.
Why Did Forest Laboratories Buy Furiex Pharmaceuticals?
Forest Laboratories bought Furiex Pharmaceuticals. Smart move?
Why Furiex Pharmaceuticals Inc. Shares Skyrocketed
Furiex shares soar after agreeing to be purchased by Forest Labs. Find out if this is a smart move or wasted money on Forest Labs' part.